Key result
LDL cholesterol uptake compromises Vγ9Vδ2 T-cell capacity to target breast cancer cells.
Why the study?
Phosphoantigens show interindividual variation in Vγ9Vδ2 T-cell activities, and the influence of metabolic resources such as lipids on their activation and function was unclear.
Does LDL cholesterol treatment inhibit the antitumor functions of human Vγ9Vδ2 T cells?
Does LDL cholesterol treatment inhibit the antitumor functions of human Vγ9Vδ2 T cells?
LDL cholesterol acts as an inhibitor of the antitumor functions of phosphoantigen-activated Vγ9Vδ2 T cells, with potential implications for T-cell-based cancer therapies.
Vγ9Vδ2 T cells, the main subset of γδ T lymphocytes in human peripheral blood, are endowed with antitumor functions such as cytotoxicity and IFNγ production. These functions are triggered upon T-cell receptor–dependent activation by non-peptidic prenyl pyrophosphates (“phosphoantigens”) that are selective agonists of Vγ9Vδ2 T cells, and which have been evaluated in clinical studies. Because phosphoantigens have shown interindividual variation in Vγ9Vδ2 T-cell activities, we asked whether metabolic resources, namely lipids such as cholesterol, could affect phosphoantigen-mediated Vγ9Vδ2 T-cell activation and function. We show here that Vγ9Vδ2 T cells express the LDL receptor upon activation and take up LDL cholesterol. Resulting changes, such as decreased mitochondrial mass and reduced ATP production, correlate with downregulation of Vγ9Vδ2 T-cell activation and functionality. In particular, the expression of IFNγ, NKG2D, and DNAM-1 were reduced upon LDL cholesterol treatment of phosphoantigen-expanded Vγ9Vδ2 T cells. As a result, their capacity to target breast cancer cells was compromised both in vitro and in an in vivo xenograft mouse model. Thus, this study describes the role of LDL cholesterol as an inhibitor of the antitumor functions of phosphoantigen-activated Vγ9Vδ2 T cells. Our observations have implications for therapeutic applications dependent on Vγ9Vδ2 T cells. Cancer Immunol Res; 6(4); 448–57.
No takes yet. Share an insight, caveat, or question.
Rodrigues et al. (2018) studied Breast cancer. LDL cholesterol was evaluated on Vγ9Vδ2 T-cell activation and functionality (IFNγ, NKG2D, and DNAM-1 expression and capacity to target breast cancer cells). LDL cholesterol uptake by activated human Vγ9Vδ2 T cells reduced their expression of IFNγ, NKG2D, and DNAM-1, compromising their capacity to target breast cancer cells in vitro and in vivo.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: